Midyear Report 2022

Midyear report 2022

High-precision delivery

medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. On September 30, 2021, medmix spun off from Sulzer. Its shares are since listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105). This is the first midyear report of medmix as an independent group of companies.
Read more about medmix here

Letter to the shareholders


Our KEY Figures

250.6 m CHF

revenue in H1 2022

24.0 %

adjusted EBITDA margin

14.3 m CHF

free cash flow generated in H1 2022

Financial Review Section

Financial and business review


Financial reporting